CAJ | 학술논문

目的:探讨手术联合人重组干扰素-α-2b(IFN-α-2b)治疗子宫内膜异位症(内异症)的效果.方法:45例内异症患者分为3组,试验组(手术+人重组IFN-α-2b联合治疗)15例, 对照组A(手术+达菲林联合治疗) 20例,对照组B(单纯手术治疗)10例.各组患者分别于术前、术后1、2、3个月,采用微粒子酶免疫化学发光法检测血清CA125 水平和用ELISA方法检测血清子宫内膜抗体(EMAb)水平.术后随访,评估临床情况,并记录联合应用人重组IFN-α-2b治疗的不良反应.结果:(1)试验组和对照组A于术后1～3个月血清CA125和EMAb水平均较术前明显降低 (均P ＜ 0.05);试验组和对照组A间术前、术后1、2、3个月血清CA125和EMAb水平差异无统计学意义(均P ＞ 0.05);试验组和对照组B间术前血清CA125和EMAb水平差异无统计学意义(均P > 0.05),而术后1个月时试验组较对照组B的EMAb水平降低(P ＜ 0.05).(2)随访观察联合使用人重组IFN-α-2b治疗后有低热、关节肌肉酸痛及胃肠道不适等不良反应,停药后症状完全消失.结论:手术联合人重组IFN-α-2b治疗内异症的CA125和EMAb的水平与联合达菲林治疗基本相似,均比单纯手术治疗效果好.
목적:탐토수술연합인중조간우소-α-2b(IFN-α-2b)치료자궁내막이위증(내이증)적효과.방법:45례내이증환자분위3조,시험조(수술+인중조IFN-α-2b연합치료)15례, 대조조A(수술+체비림연합치료) 20례,대조조B(단순수술치료)10례.각조환자분별우술전、술후1、2、3개월,채용미입자매면역화학발광법검측혈청CA125 수평화용ELISA방법검측혈청자궁내막항체(EMAb)수평.술후수방,평고림상정황,병기록연합응용인중조IFN-α-2b치료적불량반응.결과:(1)시험조화대조조A우술후1～3개월혈청CA125화EMAb수평균교술전명현강저 (균P ＜ 0.05);시험조화대조조A간술전、술후1、2、3개월혈청CA125화EMAb수평차이무통계학의의(균P ＞ 0.05);시험조화대조조B간술전혈청CA125화EMAb수평차이무통계학의의(균P > 0.05),이술후1개월시시험조교대조조B적EMAb수평강저(P ＜ 0.05).(2)수방관찰연합사용인중조IFN-α-2b치료후유저열、관절기육산통급위장도불괄등불량반응,정약후증상완전소실.결론:수술연합인중조IFN-α-2b치료내이증적CA125화EMAb적수평여연합체비림치료기본상사,균비단순수술치료효과호.
Objective:To investigate the effect of human interferon-α-2b(IFN-α-2b) in the treatment of endometriosis by detecting the levels of CA125 and endometrial antibody(EMAb). Methods: Forty-five cases with endometriosis were divided into three groups. Fifteen cases in test group (operation+IFN-α-2b), 20 cases in control group A (operation+Diphereline), 10 cases in control group B(only operation). The blood serum level of CA125 was detected by microparticle enzyme immunochemiluminescent at pre-operation, the first month, second month and third month of the post-operation; and the EMAb level was measured by enzyme linked immunosorbent assay (ELISA). The follow-up of patients was carried out after operation to evaluate the clinical appearances and record the adverse effects of the human IFN-α-2b. Results: Compared with pre-operation, the levels of CA125 and EMAb were obviously degraded in the first to third months after surgery in test group and control group A(P < 0.05). There were no significant difference in the levels of CA125 and EMAb were at pre-operation,the first month,second month and third month of the post-operation between the test group and control group A(P > 0.05). There were no significant difference in the levels of CA125 and EMAb at pre-operation between the test group and control group B(P > 0.05). However, the level of EMAb was lower the first month after operation in the test group than that of control group B. In the follow-up, the adverse effects of the human interferon-α-2b were observed including low-grade fever, articular muscle soreness and gastrointestinal tract complaints. These appearances completely disappeared after drug withdrawal. It had less impact on the menstruation. Conclusion: The levels of CA125 and EMAb were similar in treatment of endometriosis with human IFN-α-2b and with Diphereline. Both of the treatments are better than the pure surgery. It has less impact on the menstruation and can avoid menostasia.